8:00 am Registration Opens
8:45 am Chair’s Opening Remarks – Where Are We & Where Are We Going? Overview of Recent Exciting NSCLC Abstracts
Emerging Approaches to Targeting NSCLC
9:00 am Progress in Newly Diagnosed Actionable Mutations
Synopsis
• Rationale & updates for novel TKIs
• Discussing the safety and efficacy of novel TKIs that target the eight molecular subtypes/currently actionable alterations
• Latest data & future directions
9:30 am KRAS G12C Development: New Opportunities…
Synopsis
- Exploring adagrasib preclinical combinations
- Looking into patient combos, brain met data and more
10:00 am Speed Networking
11:00 am Morning Refreshments
Drug Development Progress in Late-Line Non-Small Cell Lung Cancer
12:00 pm Investigating Safety & Efficacy of Novel Immunotherapies in Clinical Investigation in NSCLC
Synopsis
- Understanding the translational timeline, patient population and
combination rationale - Exploring the latest clinical data, challenges and future directions into earlier lines
12:30 pm Panel Discussion: Exploring the Strategic Challenges of Moving Forward a Drug You Want to Combine with PD-1 in Chemo+PD-1 Progressors
Synopsis
- Understanding the different current comparators and benchmarks
- Exploring the differences in PD-1 naïve and PD-1 progressors
- Dissecting why sometimes beating chemo and PD-1 could be an unachievable bar
- Discussing whether with late-line in-effectivity, how you know it won’t work in early line?
- Considering the health authorities’ standards on the matter
Understanding PD-1 Resistance & Improved Dissection of Patient Populations in Later-Line NSCLC
2:30 pm Exploring MT-6402, a Novel Engineered Toxin Body Targeting PD-L1—Interim Data of a Dose Escalation Trial in Patients with Relapsed/Refractory PD-L1-Expressing Solid Tumors
2:30 pm Exploring BLU-945 in EGFR-Mutated NSCLC
Synopsis
- Exploring the latest translational research
- Discussing potential combinations and treatment line
- Latest data and future directions
3:00 pm Poster Session
Optimizing Sequencing & Combination Rationale in Later Lines of Therapy
3:30 pm Informed By The Tumor: The Power of a Personalized ctDNA Assay For MRD Detection & Monitoring in NSCLC
Synopsis
- Latest clinical data from 2022 publications and presentations
- Advantages of a personalized, tumor-informed ctDNA assay for molecular residual
disease detection - Applications of Signatera in clinical trial design to maximize trial success, and
accelerate time to data readout
4:00 pm Advancements in ADCs for later-line NSCLC
Synopsis
- Exploring the latest translational research
- Discussing potential combinations and treatment line
- Latest data and future directions
4:30 pm Synergy is a 4 Letter Word: Lessons of Independent Action as an Explanation for the Efficacy of Cancer Clinical Combination Therapies
Synopsis
– Immuno oncology drugs are failing at an unprecedented rate, perhaps because too much reliance has been placed on pre-clinical thinking about synergy
– Based on the mathematics of Independent Action, synergy has not been seen in any immuno oncology registration trials to date
– To progress development of combinations of ADC and PD-1 immune checkpoint inhibitors, the field must adapt more rigorous mathematic thinking about combination results
5:00 pm Targeted Therapies in Late Lines of NSCLC: Sequencing & Combination Regimens
Synopsis
- Relevance of sequencing drugs to address resistance
- Combination regimens to improve efficacy
- Addressing mechanisms of resistance to targeted therapies
5:30 pm Chair’s Closing Remarks & End of Day 1
